Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer.

Dianyun Ren, Gengdu Qin, Jingyuan Zhao, Yan Sun, Bin Zhang, Dan Li, Bo Wang, Xin Jin, Heshui WuPubMed 2020

TL;DR

Metformin, a common anti-diabetes drug, shows promise as an anti-cancer agent, particularly in pancreatic cancer. This study reveals a novel mechanism: metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT signaling in pancreatic cancer cells, leading to enhanced immune cell infiltration and tumor suppression. This discovery suggests a new therapeutic strategy, combining metformin with STING agonists for improved pancreatic cancer treatment.

What Problem Does This Paper Address?

Pancreatic ductal adenocarcinoma (PDAC) is a particularly aggressive cancer with a dismal prognosis and limited treatment options. While immunotherapy, specifically immune checkpoint blockade (ICB), has shown success in other cancers, it's largely ineffective in PDAC. This is attributed to the immunosuppressive tumor microenvironment (TME) characteristic of PDAC. Metformin, a widely used anti-diabetic drug, has demonstrated anti-tumor effects in various cancers, including promoting immune cell infiltration. However, the precise mechanisms by which metformin exerts its anti-tumor effects in PDAC, particularly concerning immune modulation, remain unclear. This paper aims to elucidate these mechanisms, focusing on the STING pathway and its potential role in metformin's anti-PDAC activity.

Methods

The researchers employed a multi-pronged approach:

  • Cell Culture and Western Blotting: Standard cell lines (PANC-1, BxPC-3, SW1990) were used to investigate the effects of metformin on protein expression levels of key molecules like STING, IRF3, and phosphorylated AKT (p-AKT).
  • Quantitative Real-Time PCR (qRT-PCR): This technique was used to measure mRNA expression levels of STING and IFN-β in response to metformin treatment.
  • Enzyme-Linked Immunosorbent Assay (ELISA): ELISA was employed to quantify the protein levels of IFN-β, a key cytokine in the STING pathway.
  • Pharmacological Interventions: Specific inhibitors (MK2206 for AKT) and activators (SC79 for AKT) were used to dissect the role of the AKT pathway in metformin's effects. The STING agonist 2'3'-cGAMP was used to explore synergistic effects.
  • Syngeneic Tumor Models: Mouse models (Panc02 cells in C57BL/6 mice) were utilized to assess the in vivo efficacy of metformin, alone and in combination with 2'3'-cGAMP, on tumor growth, survival, and immune cell infiltration.
  • Flow Cytometry: This technique was used to analyze the infiltration of specific immune cell populations (CD4+ and CD8+ T cells) within tumors.
  • Bioinformatics Mining: Publicly available datasets (TIMER and GEPIA) were analyzed to explore the correlation between STING/IFN-β expression and immune cell infiltration in human PDAC.

Datasets

The study utilized publicly available datasets for bioinformatics analysis:

  • TIMER (Tumor IMmune Estimation Resource): Used to assess the correlation between STING mRNA levels and the infiltration of CD4+ and CD8+ T cells in pancreatic adenocarcinoma (PAAD).
  • GEPIA (Gene Expression Profiling Interaction Analysis): Used to examine the correlation between STING and IFNB1 mRNA levels in PAAD.

No new datasets or benchmarks were introduced in this paper.

Key Insights and Ideas

  • Metformin Activates STING in PDAC Cells: The study demonstrates that metformin treatment significantly upregulates both mRNA and protein levels of STING in pancreatic cancer cell lines. This effect is dose- and time-dependent, suggesting a direct impact of metformin on STING expression.
  • STING-IRF3-IFN-β Pathway Activation: Metformin not only increases STING but also activates the downstream STING/IRF3/IFN-β signaling cascade, evidenced by increased phosphorylation of IRF3 and production of IFN-β. This pathway is crucial for initiating anti-tumor immune responses.
  • AKT Inhibition is Key: A critical finding is that metformin's ability to upregulate STING is mediated by the inhibition of AKT phosphorylation. This suggests a direct link between the AKT signaling pathway and STING regulation in pancreatic cancer.
  • Synergistic Effects with STING Agonists: Combining metformin with 2'3'-cGAMP, a STING pathway agonist, resulted in synergistic activation of the STING/IRF3/IFN-β pathway and significantly enhanced anti-tumor effects in vivo.
  • Enhanced Immune Cell Infiltration: Metformin, especially in combination with 2'3'-cGAMP, significantly promoted the infiltration of CD4+ and CD8+ T cells into the tumor microenvironment, a crucial step for effective anti-tumor immunity.

Key Results

  • Metformin treatment led to a dose- and time-dependent increase in STING mRNA and protein levels in PANC-1, SW1990, and BxPC-3 cell lines.
  • Metformin treatment increased the phosphorylation of IRF3 and the production of IFN-β in pancreatic cancer cells.
  • Metformin inhibited AKT phosphorylation in these cell lines.
  • The AKT inhibitor MK2206 mimicked metformin's effect on STING, while the AKT activator SC79 reversed it, confirming AKT's inhibitory role.
  • Combination therapy of metformin and 2'3'-cGAMP showed synergistic effects in activating the STING/IRF3/IFN-β pathway in vitro.
  • In vivo studies demonstrated that metformin and 2'3'-cGAMP significantly suppressed tumor growth and prolonged survival in a mouse model of pancreatic cancer.
  • The combination therapy also led to a significant increase in CD4+ and CD8+ T cell infiltration in tumors.

Limitations and Future Work

  • In Vitro vs. In Vivo: While the study provides strong evidence from cell lines, the translation of these findings to the complex in vivo tumor microenvironment is crucial.
  • Specific STING Agonists: The study focused on 2'3'-cGAMP. Future research could explore other STING agonists and their combinations with metformin.
  • Clinical Translation: The authors emphasize the need for future clinical studies to investigate the benefits of metformin combined with existing or novel immunotherapies, particularly STING-activating agents, in pancreatic cancer patients.
  • Broader Immune Cell Interactions: While CD4+ and CD8+ T cells were highlighted, further investigation into the impact of metformin and STING activation on other immune cell populations within the TME could provide a more comprehensive understanding.

Summary updated

Abstract

The anti-diabetes drug metformin has emerged as a promising antitumor agent in pancreatic ductal adenocarcinoma (PDAC) among other cancers by promoting the infiltration of immune cells in the tumor microenvironment (TME). However, the mechanisms underlying the antitumor effects of metformin in PDAC remain unclear. In this study, we revealed that metformin induced stimulator of interferon genes (STING) expression in pancreatic cancer cells in a dose- and time-dependent manner. Metformin also activated the STING/IRF3/IFN-β pathway by inhibiting AKT signaling in PDAC cells. Importantly, the combination of metformin with the STING agonist 2'3'-cGAMP exerted synergistic effects in activating the STING/IRF3/IFN-β pathway in pancreatic cancer cells. Additionally, metformin augmented the antitumor effects of 2'3'-cGAMP in mouse models by enhancing the infiltration of T cells in the TME. These findings unveiled a previously unknown mechanism contributing to the antitumor effects of metformin in PDAC, and provide a rationale for its use in combination with existing or novel immunotherapies.
BibTeX
@inproceedings{ren2020metformin,
  author = {Dianyun Ren and Gengdu Qin and Jingyuan Zhao and Yan Sun and Bin Zhang and Dan Li and Bo Wang and Xin Jin and Heshui Wu},
  title = {{Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer.}},
  booktitle = {PubMed},
  year = {2020},
}
Figure